Articles

SBS builds on its success

After changing up the format slightly last year, SBS makes some more thematic shifts to broaden and deepen the educational offerings
Written byJeffrey Bouley
| 12 min read

PHOENIX—High-tech tools are certainly a huge part of drug discovery and development, but this year, the Society for Biomolecular Sciences (SBS) is taking the content of the SBS 16th Annual Conference & Exhibition somewhat away from the traditionally heavy technology focus and bringing in some of the broader scientific issues involved with drug discovery.

The 2010 meeting, to be held at the Phoenix Convention Center April 11 to 15, is designed to build upon the refinements made to the format in recent years, according to conference program co-chairmen Keith Moore and Keith Wood.

Specifically, they say, the 2010 meeting will be organized around six mini-symposia, each lasting one-and-a-half days and covering key areas of relevance from technological, functional and therapeutic perspectives.

Three of the sessions will run in parallel on April 12-13 and the other three on April 14-15. This structure will provide for 15 presentations to cover each topic in greater depth, Moore and Wood note, allowing time to address the crucial issues and recent scientific developments in an integrated and coherent manner, drawing on contributions from a range of disciplines.

"This format does depart from the collection of independent half-day sessions traditionally offered at the conference," Wood says, "but it also builds on the success of the 2009 annual conference in Lille, France, which was organized around four thematic tracks. That worked well and was well received. One track in particular, structured as a mini-symposium on the GPCR target family, met with strong success."

The 2010 annual conference will extend this model by offering multiple mini-symposia covering the core SBS disciplines, an emerging target class and lead discovery in selected therapeutic areas.

For core capabilities in lead discovery, presentations will be organized into two non-concurrent sessions. The first is Critical Reagents, which will focus on the design of synthetic and natural product libraries, sample storage, compound quality control and distribution and bioreagent preparation for lead discovery. The second, Assays and Automation, will cover best practices in automation and miniaturization, novel screening technologies for hit discovery and lead optimization. Between the two tracks, the aim is to cover the latest developments in the evaluation and deployment of new approaches, technologies and products to enable novel research paradigms, or enhance the quality and cost efficiency of lead discovery.

The Epigenetics session does the duty of highlighting the emerging target class most of interest to SBS this year. Epigenetic targets represent a new and emerging protein class with significant potential roles in the pathogenesis and therefore the treatment of human disease, Moore and Wood say.

The other three sessions cover lead discovery in specific therapeutic areas—an important consideration in programming for the conference, Moore and Wood maintain, because "orthogonal to the technology, discipline and functional alignment of lead discovery is the coordinated application of these approaches to focused therapeutic areas. Working closely with disease experts, scientists within the core platforms develop approaches and capabilities tailored to the specific requirements and challenges of lead discovery and optimization in a specific therapeutic area."

These three sessions will cover the integration of recent scientific and technological advances to identify targets, leads (both small molecule and biopharmaceutical), and clinical candidates in the areas of immunoinflammation, oncology and neurosciences.

"By presenting a marriage of scientific insight and technological achievements, these mini-symposia will offer various perspectives relevant to their respective fields ranging from target biology to lead optimization," Wood says.

Oncology will address identification of valid and tractable targets, through the design and prosecution of in vitro assays, to the selection of appropriate molecules for progression toward the clinic, he says. Immunoinflammation will highlight breakthrough areas of new science, focusing on innate immunity, adaptive immunity and inflammation and its resolution. Neurosciences will address target classes that mediate cellular signaling pathways, ion channels, membrane transporters and G-protein coupled receptors, focusing on unique technologies for improving lead identification.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A researcher wearing a white lab coat and blue nitrile glove holds a tiny brown glass sample vial with a blue cap in front of an autosampler carousel on a HPLC laboratory analyzer.
Hear an expert perspective on the hidden variables affecting chromatographic methods and how to build more robust, reliable workflows.
Researcher using a laptop with a digital DNA helix and molecular biology graphics overlaid, illustrating connected workflows for sequence design, data management, and therapeutic research.
To keep pace with modern drug discovery, researchers need molecular biology approaches that can support complexity without slowing down the science.
Shaping Science graphic featuring the question “How can labs become truly sustainable?” and a photo of James Connelly, Chief Executive Officer of My Green Lab.
Creating more sustainable laboratories depends on practical changes that strengthen scientific performance while reducing environmental impact.